Validation of the cancer-specific utility measure EORTC QLU-C10D using evidence from four lung cancer trials covering six country value sets

RECOMMENDED

Lung CancerFurther Publications

Physical activity and lung cancer screening (PALS): feasibility randomised controlled trial of exercise and physical activity in lung cancer screening

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Respir Res

Bonney A, Granger CL, Steinfort D, Patrick C, Marshall HM, Fong KM, Manser R

doi: 10.1186/s12931-025-03158-0

RECOMMENDED

Lung Cancer

An international and multidisciplinary EORTC survey on resectability of stage III non-small cell lung cancer

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Lung Cancer

Houda I, Bahce I, Dickhoff C, Kroese TE, Kroeze SGC, Mariolo AV, Tagliamento M, Moliner L, Brandão M, Pretzenbacher Y, Edwards J, Opitz I, Brunelli A, Guckenberger M, van Schil PE, Popat S, Blum T, Faivre-Finn C, de Ruysscher D, Remon J, Berghmans T, Dingemans AC, Besse B, Hendriks LEL

doi: 10.1016/j.lungcan.2024.108061

RECOMMENDED

Lung Cancer

Software using artificial intelligence for nodule and cancer detection in CT lung cancer screening: systematic review of test accuracy studies

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 3 Recommended by Dr Marcus Hesse, Faculty Member

Thorax

Geppert J, Asgharzadeh A, Brown A, Stinton C, Helm EJ, Jayakody S, Todkill D, Gallacher D, Ghiasvand H, Patel M, Auguste P, Tsertsvadze A, Chen YF, Grove A, Shinkins B, Clarke A, Taylor-Phillips S

doi: 10.1136/thorax-2024-221662

RECOMMENDED

Lung Cancer

Stage-Specific Guideline Concordant Treatment Impacts on Survival in Nonsmall Cell Lung Cancer: A Novel Quality Indicator

★ 1 Recommended by Dr Martin Frey, Faculty Member

Clin Lung Cancer

Tissera S, Billah B, Brand M, Karim MN, Antippa P, Blum R, Caldecott M, Conron M, Faisal W, Harden S, Olesen I, Parente P, Richardson G, Samuel E, See K, Underhill C, Wright G, Zalcberg J, Stirling RG

doi: 10.1016/j.cllc.2024.08.012

RECOMMENDED

Lung Cancer

Optimum diagnostic pathway and pathologic confirmation rate of early stage lung cancer: Results from the VIOLET randomised controlled trial

★ 1 Recommended by Dr Martin Frey, Faculty Member

Lung Cancer

Harris RA, Stokes EA, Batchelor TJP, Internullo E, West D, Jordan S, Nicholson AG, Paul I, Jacobs C, Shackcloth M, Feeney S, Anikin V, McGonigle N, Steyn R, Kalkat M, Stavroulias D, Havinden Williams M, Qadri S, Dobbs K, Zamvar V, Macdonald L, Kaur S, Rogers CA, Lim E, VIOLET trialists

doi: 10.1016/j.lungcan.2024.108070

RECOMMENDED

Lung Cancer

ctDNA can detect minimal residual disease in curative treated non-small cell lung cancer patients using a tumor agnostic approach

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Lung Cancer

Rosenlund L, Guldbrandsen K, Ahlborn LB, Bloch M, Skougaard K, Albrecht-Beste E, Nellemann HM, Krakauer M, Gørtz PM, Fledelius J, Nielsen AL, Holdgaard PC, Nielsen SS, Grüner JM, Højsgaard A, Petersen RH, Møller LB, Dahl M, Frank MS, Ehlers JH, Saghir Z, Pøhl M, Borissova S, Land LH, Kristiansen C, McCulloch T, Mortensen LS, Christophersen MS, Hilberg O, Rasmussen TL, Simonsen Schwaner SH, Laursen CB, Bodtger U, Lonsdale MN, Meyer CN, Gerke O, Mortensen J, Rasmussen TR, Hjorthaug K, Larsen KR, Meldgaard P, Fischer BM, Sorensen BS

doi: 10.1016/j.lungcan.2025.108528

RECOMMENDED

Lung Cancer

Identification and Treatment of Lung Cancer Oncogenic Drivers in a Diverse Safety Net Setting

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Clin Lung Cancer

Narra K, Ghabach B, Athipatla V, Blackwell JM, Teigen KJ, Bullock JC, Diaz A, Gerber DE, von Itzstein MS

doi: 10.1016/j.cllc.2024.08.014

RECOMMENDED

Further Publications

Long-term survival from a randomized controlled trial of lobectomy by video-assisted thoracoscopic surgery versus thoracotomy for early-stage lung cancer

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Eur J Cardiothorac Surg

Dittberner FA, Bendixen M, Licht PB

doi: 10.1093/ejcts/ezaf017

Lung Cancer

Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS)

Clin Lung Cancer

Sakata Y, Saito G, Sakata S, Yamaguchi T, Tamiya M, Suzuki H, Shibaki R, Okada A, Yokoyama T, Matsumoto H, Otsuki T, Sato Y, Uchida J, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga J, Sakagami T

doi: 10.1016/j.cllc.2025.05.015

Related content

Physical activity and lung cancer screening (PALS): feasibility randomised controlled trial of exercise and physical activity in lung cancer screening

An international and multidisciplinary EORTC survey on resectability of stage III non-small cell lung cancer

Software using artificial intelligence for nodule and cancer detection in CT lung cancer screening: systematic review of test accuracy studies

Stage-Specific Guideline Concordant Treatment Impacts on Survival in Nonsmall Cell Lung Cancer: A Novel Quality Indicator

Optimum diagnostic pathway and pathologic confirmation rate of early stage lung cancer: Results from the VIOLET randomised controlled trial

ctDNA can detect minimal residual disease in curative treated non-small cell lung cancer patients using a tumor agnostic approach

Identification and Treatment of Lung Cancer Oncogenic Drivers in a Diverse Safety Net Setting

Long-term survival from a randomized controlled trial of lobectomy by video-assisted thoracoscopic surgery versus thoracotomy for early-stage lung cancer

Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS)